Viva Biotech Holdings
Viva Biotech Holdings, a leading player in the biotechnology sector, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2008, the company has established itself as a prominent provider of drug discovery services, specialising in structure-based drug design and high-throughput screening. Viva Biotech's unique offerings include its proprietary technology platforms that enhance the efficiency of drug development processes, setting it apart in a competitive market. With a strong focus on innovation, the company has achieved significant milestones, including collaborations with major pharmaceutical firms and a robust portfolio of successful projects. Recognised for its expertise and commitment to advancing biopharmaceutical research, Viva Biotech Holdings continues to solidify its position as a trusted partner in the global biotech landscape.
DitchCarbon Score
How does Viva Biotech Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Viva Biotech Holdings's score of 28 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Viva Biotech Holdings's reported carbon emissions
In 2025, Viva Biotech Holdings reported total carbon emissions of approximately 371,399,000 kg CO2e, with a significant majority, about 369,861,000 kg CO2e, classified under Scope 3 emissions. This includes emissions from purchased goods and services (approximately 280,338,000 kg CO2e) and upstream transportation and distribution (about 42,044,000 kg CO2e). The company's Scope 1 and 2 emissions were reported at approximately 1,538,000 kg CO2e (market-based). For the previous year, 2024, total emissions were approximately 411,661,000 kg CO2e, with Scope 3 emissions again dominating at about 409,994,000 kg CO2e. The Scope 1 and 2 emissions for 2024 were around 1,667,000 kg CO2e (market-based). In 2023, the total emissions were approximately 415,007,000 kg CO2e, with Scope 3 emissions at about 413,340,000 kg CO2e. The Scope 1 and 2 emissions for that year were approximately 1,667,000 kg CO2e (market-based). Viva Biotech Holdings has not disclosed any specific reduction targets or initiatives, nor does it appear to have cascaded data from a parent organization. The company has not committed to any Science-Based Targets Initiative (SBTi) reduction targets or other formal climate pledges. The absence of detailed reduction strategies suggests a need for further commitment to climate action within the industry context.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Scope 1 | 958,111.2 | - | - | - |
| Scope 2 | 36,499,030 | - | - | - |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Viva Biotech Holdings is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
